Statin add-on therapy in the antipsychotic treatment of schizophrenia

A meta-analysis

Ikuo Nomura, Taro Kishi, Toshikazu Ikuta, Nakao Iwata

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A comprehensive meta-analysis of statin add-on therapy in the antipsychotic treatment of schizophrenia was conducted. Data from previous studies, prior to 8/21/2017, was obtained from Scopus, PubMed, PsycINFO, and Cochrane Library. Both a systematic review and meta-analysis were conducted with patient data from randomized placebo-controlled trials (RCTs) to compare statins with placebo in order to calculate effect size. Across the five RCTs (mean duration: 9.2 weeks), 236 adult patients with schizophrenia were randomly selected to receive either placebo (n=117) or statins (n=119). Pooled statin add-on therapy showed significant superiority over placebo in the improvement of Positive and Negative Syndrome Scale (PANSS) total scores (mean difference=−1.96; 95% confidence interval, −2.94 to −0.98; p<0.0001; I2=0%; N=4, n=174). However, there were no statistically significant differences in other efficacy outcomes between the two treatment groups. Statin did not have a significant difference in its incidence of discontinuation or have individual adverse events compared to placebo. Our results suggest that statins may have considerable potential as an add-on therapy for schizophrenia. However, determining the effectiveness of this treatment in clinical practice requires future investigation due to limitations of the current evidence-base including small sample, potential for publication and selection biases and short duration of follow-up.

Original languageEnglish
Pages (from-to)41-47
Number of pages7
JournalPsychiatry Research
Volume260
DOIs
Publication statusPublished - 01-02-2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Antipsychotic Agents
Meta-Analysis
Schizophrenia
Placebos
Therapeutics
Randomized Controlled Trials
Publication Bias
Selection Bias
PubMed
Libraries
Confidence Intervals
Incidence

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Nomura, Ikuo ; Kishi, Taro ; Ikuta, Toshikazu ; Iwata, Nakao. / Statin add-on therapy in the antipsychotic treatment of schizophrenia : A meta-analysis. In: Psychiatry Research. 2018 ; Vol. 260. pp. 41-47.
@article{1f17e65e8731416fb4a30c6fe250c902,
title = "Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis",
abstract = "A comprehensive meta-analysis of statin add-on therapy in the antipsychotic treatment of schizophrenia was conducted. Data from previous studies, prior to 8/21/2017, was obtained from Scopus, PubMed, PsycINFO, and Cochrane Library. Both a systematic review and meta-analysis were conducted with patient data from randomized placebo-controlled trials (RCTs) to compare statins with placebo in order to calculate effect size. Across the five RCTs (mean duration: 9.2 weeks), 236 adult patients with schizophrenia were randomly selected to receive either placebo (n=117) or statins (n=119). Pooled statin add-on therapy showed significant superiority over placebo in the improvement of Positive and Negative Syndrome Scale (PANSS) total scores (mean difference=−1.96; 95{\%} confidence interval, −2.94 to −0.98; p<0.0001; I2=0{\%}; N=4, n=174). However, there were no statistically significant differences in other efficacy outcomes between the two treatment groups. Statin did not have a significant difference in its incidence of discontinuation or have individual adverse events compared to placebo. Our results suggest that statins may have considerable potential as an add-on therapy for schizophrenia. However, determining the effectiveness of this treatment in clinical practice requires future investigation due to limitations of the current evidence-base including small sample, potential for publication and selection biases and short duration of follow-up.",
author = "Ikuo Nomura and Taro Kishi and Toshikazu Ikuta and Nakao Iwata",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.psychres.2017.11.033",
language = "English",
volume = "260",
pages = "41--47",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

Statin add-on therapy in the antipsychotic treatment of schizophrenia : A meta-analysis. / Nomura, Ikuo; Kishi, Taro; Ikuta, Toshikazu; Iwata, Nakao.

In: Psychiatry Research, Vol. 260, 01.02.2018, p. 41-47.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statin add-on therapy in the antipsychotic treatment of schizophrenia

T2 - A meta-analysis

AU - Nomura, Ikuo

AU - Kishi, Taro

AU - Ikuta, Toshikazu

AU - Iwata, Nakao

PY - 2018/2/1

Y1 - 2018/2/1

N2 - A comprehensive meta-analysis of statin add-on therapy in the antipsychotic treatment of schizophrenia was conducted. Data from previous studies, prior to 8/21/2017, was obtained from Scopus, PubMed, PsycINFO, and Cochrane Library. Both a systematic review and meta-analysis were conducted with patient data from randomized placebo-controlled trials (RCTs) to compare statins with placebo in order to calculate effect size. Across the five RCTs (mean duration: 9.2 weeks), 236 adult patients with schizophrenia were randomly selected to receive either placebo (n=117) or statins (n=119). Pooled statin add-on therapy showed significant superiority over placebo in the improvement of Positive and Negative Syndrome Scale (PANSS) total scores (mean difference=−1.96; 95% confidence interval, −2.94 to −0.98; p<0.0001; I2=0%; N=4, n=174). However, there were no statistically significant differences in other efficacy outcomes between the two treatment groups. Statin did not have a significant difference in its incidence of discontinuation or have individual adverse events compared to placebo. Our results suggest that statins may have considerable potential as an add-on therapy for schizophrenia. However, determining the effectiveness of this treatment in clinical practice requires future investigation due to limitations of the current evidence-base including small sample, potential for publication and selection biases and short duration of follow-up.

AB - A comprehensive meta-analysis of statin add-on therapy in the antipsychotic treatment of schizophrenia was conducted. Data from previous studies, prior to 8/21/2017, was obtained from Scopus, PubMed, PsycINFO, and Cochrane Library. Both a systematic review and meta-analysis were conducted with patient data from randomized placebo-controlled trials (RCTs) to compare statins with placebo in order to calculate effect size. Across the five RCTs (mean duration: 9.2 weeks), 236 adult patients with schizophrenia were randomly selected to receive either placebo (n=117) or statins (n=119). Pooled statin add-on therapy showed significant superiority over placebo in the improvement of Positive and Negative Syndrome Scale (PANSS) total scores (mean difference=−1.96; 95% confidence interval, −2.94 to −0.98; p<0.0001; I2=0%; N=4, n=174). However, there were no statistically significant differences in other efficacy outcomes between the two treatment groups. Statin did not have a significant difference in its incidence of discontinuation or have individual adverse events compared to placebo. Our results suggest that statins may have considerable potential as an add-on therapy for schizophrenia. However, determining the effectiveness of this treatment in clinical practice requires future investigation due to limitations of the current evidence-base including small sample, potential for publication and selection biases and short duration of follow-up.

UR - http://www.scopus.com/inward/record.url?scp=85034744746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034744746&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2017.11.033

DO - 10.1016/j.psychres.2017.11.033

M3 - Article

VL - 260

SP - 41

EP - 47

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -